Growth Factor Antagonists in Prostatic Cancer: Suramin and Cytotoxic Polyamines as Potential Therapy

  • Warren D. W. Heston


Prostatic Cancer is the leading site for cancer in men over 50 years of age and is the second leading cause of cancer deaths in the US (1). Clinically manifest prostatic cancer is more common in the US than in Japan while the incidence of latent cancer is similar between the two countries. The incidence of prostatic cancer of first generation males of Japanese living in the US is the same as that of US males. The implication is that life style differences are important for the progression of the disease. As prostatic cancer is refractory to most standard chemotherapeutic agents and hormone therapy is only palliative it may be that it will be easier to prevent the progression of prostatic cancer than to cure it. Consideration should be given to 3 omega unsaturated fatty acids, which are common in fish oils, as possible agents in a study of prevention of progression. The 3 omega unsaturated fatty acids have proven beneficial in the prevention of cancer and reduced the growth of prostatic cancer in nude mice (2,3). Other cultural differences in nutrition such as the use of green tea should be investigated to identify other potential anti-tumor progression factors.


Prostatic Cancer LNCaP Cell Diamine Oxidase Human Prostatic Cancer Cell Line Polyamine Synthesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Silverburg, E., and Lubera, J.A. Cancer Statistics, CA 39:3–22, 1989.Google Scholar
  2. 2.
    Telang, N.T., Basu, A., Kurihara, H., Osborne, M.P. and Modak, M.J. Modulation in the expression of murine mammary tumor virus, ras proto-oncogene and of alveolar hyperplasia by fatty acids in mouse mammary explant cultures. Anticancer Res., 8:971–976, 1988.PubMedGoogle Scholar
  3. 3.
    Karmali, R.A., Reichel, P., Cohen, L.A., Terano, T., Hirai, A., Tamura, Y. and Yoshida, S. The effects of dietary omega-3 fatty acids on the DU-145 transplantable human prostatic tumor. Anticancer Res., 7:1173–1180, 1987.PubMedGoogle Scholar
  4. 4.
    Raina, A., Pajula, R., Eloranta, T. A rapid assay for spermidine and spermine synthesis: distribution of polyamine synthesizing enzymes and methionine adenosyltransferase in rat tissues. FEBS Lett., 76:252–256, 1976.CrossRefGoogle Scholar
  5. 5.
    Pegg, A.E., Lockwood, D.H. and Williams-Ashman, H.G. Concentrations of polyamines and their enzymic synthesis during androgen-induced prostatic growth. Biochem. J., 117:17–31, 1970.PubMedGoogle Scholar
  6. 6.
    Heston, W.D.W., Kadmon, D. and Fair, W.R Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor α-DFMO. The Prostate, 3:383–389, 1982.PubMedCrossRefGoogle Scholar
  7. 7.
    Tabor, C.W. and Tabor, H. Polyamines. Ann. Rev. Biochem., 53:740–790, 1984.CrossRefGoogle Scholar
  8. 8.
    Pegg, A.E. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res., 48:759–774, 1988.PubMedGoogle Scholar
  9. 9.
    Porter, C.W. and Sufrin, J.R Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential chemotherapeutic strategy. Anticancer Res., 6:535–535, 1986.Google Scholar
  10. 10.
    Seppanen P., Alhonen-Hongisto, L. and Janne, J. Death of tumor cells in response to the use of a stimulated polyamine uptake for the transport of MGBG. Eur. J. Biochem., 18:571–576, 1981.CrossRefGoogle Scholar
  11. 11.
    Herr, H.W., Kleinert, E.L., Relyea, N.M. and Whitmore, W.F. Jr. Potentiation of MGBG by DFMO in rat prostate. Cancer, 53:1294–1296, 1984.PubMedCrossRefGoogle Scholar
  12. 12.
    Romijin, J.C., Van Steenbruge, G.J. and Schroeder, F.H. Effects of polyamine antimetabolites in the growth rate of human prostatic tumors transplantable into nude mice. Fouth int. workshop on immune deficient animals. (Karger, Basel) pp. 370, 1984.Google Scholar
  13. 13.
    Persson, L., Holm, I., Asle, A. and Heby, O. Curative effect of DFMO on mice bearing mutant L1210 leukemia cells deficient in polyamine uptake. Cancer Res., 48:4807–4811, 1988.PubMedGoogle Scholar
  14. 14.
    Kadmon, D. and Heston, W.D.W. Manuscript in preparation.Google Scholar
  15. 15.
    Heston, W.D.W., Kadmon, D., Covey, D.F. and Fair, W.R Differential effect of DFMO on the in vivo uptake of 14C-labeled polyamines and MGBG by a prostate derived tumor. Cancer Res., 44:1034–1040, 1984.PubMedGoogle Scholar
  16. 16.
    Heston, W.D.W., Yang, C-R., Pliner, L., Russo, P. and Covey, D.F. Cytotoxic activity of a polyamine analog, monoaziridinyl putrescine, against the PC-3 human prostatic carcinoma cell line. Cancer Res., 47:3627–3631, 1987.PubMedGoogle Scholar
  17. 17.
    Welch, M.J., Coleman, R.E., Straatman, M.G., Asberry, B.E., Primeau, J.L., Fair, W.R. and Ter-Pergossian, M.-M. C11-labeled methylated polyamine analogs: uptake in prostate and tumor in animal models. J. Nuel. Med., 18:74–78, 1977.Google Scholar
  18. 18.
    Kadmon, D., Welsh, M.J., and personal communication.Google Scholar
  19. 19.
    Bergeron, R.J. Methods for the selective modification of spermidine and its homologs. Acc. Chem. Res., 19:105–113, 1986.CrossRefGoogle Scholar
  20. 20.
    Bergeron, R.J., Hawthorne, T.R., Vinson, J.R.T., Beck, D.F. Jr. and Igeno, M.J. Role of the methylene backbone in the antiproliferative activity of polyamine analogs on L1210 cells. Cancer Res., 49:2959–2964, 1989.PubMedGoogle Scholar
  21. 21.
    Schuber, F. Influence of polyamines on membrane functions. Biochem. J., 260:1–10, 1989.PubMedGoogle Scholar
  22. 22.
    Marton, L.J. Effects of treatment with DNA-directed cancer chemotherapeutic agents after polyamine depletion. Pharmacol. Ther., 32:183–190, 1987.PubMedCrossRefGoogle Scholar
  23. 23.
    Scher, H., Yagoda, A., Ahmed, T., et al. Phase II trial of mitoguazone in patients with hormone resistant adenocarcinoma of the prostate. J. Clin. Oncol., 3:224–229, 1989.Google Scholar
  24. 24.
    Story, M.T., Sassa, J., Jacobs, S.C. and Lawson, R.K Prostatic growth factor: purification and structural relationship to basic fibroblast growth factor. Biochem., 26:3843–3849, 1987.CrossRefGoogle Scholar
  25. 25.
    Matuo, Y., Nishi, N. and Wada, F. Growth factors in the prostate. Arch. Androl., 19:193–210, 1987.PubMedCrossRefGoogle Scholar
  26. 26.
    Matuo, Y., Nishi Matsui, S., Sandberg, A.A., Issacs, J.T. and Wada, F. Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor. Cancer Res., 47:188–192, 1987.PubMedGoogle Scholar
  27. 27.
    Mannson, P.F., Adams, P., Kan, M. and McKeehan W.L. Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res., 49:1485–1494, 1989.Google Scholar
  28. 28.
    Mydlo, J.H., Bulbul, M.A., Richon, V.M., Heston, W.D.W. and Fair, W.R. Heparin-binding growth factor isolated from human prostatic extracts. The Prostate, 12:343–355, 1988.PubMedCrossRefGoogle Scholar
  29. 29.
    Mydlo, J.H., Michaeli, J., Heston, W.D.W. and Fair, W.R. Expression of basic fibroblast growth factor mRNA in BPH and prostatic carcinoma. The Prostate, 13:241–247, 1988.PubMedCrossRefGoogle Scholar
  30. 30.
    Smith, E.P., Russell, W.E., French, F.S. and Wilson, E.M. A form of basic FGF is secreted into the adluminal fluid of the rat coagulating gland (anterior prostate). The Prostate, 14:353–365, 1989.PubMedCrossRefGoogle Scholar
  31. 31.
    Nishi, N., Matuo, Y., Kuritomi, K., Takenaka, I., Usami, M., Kotake, T. and Wada, F: Comparative analysis of growth factors in normal and pathologic human prostates. The Prostate, 13:39–48, 1988.PubMedCrossRefGoogle Scholar
  32. 32.
    Coffey, R.J., Leoff, E.B., Shipley, G.D, and Moses, H.L. Suramin inhibition of growth factor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol., 132:143–148, 1987.PubMedCrossRefGoogle Scholar
  33. 33.
    Stein, C.A., LaRocca, R.V., McAtee, T.R. and Myers, C.E. Suramin an anticancer drug with a unique mechanism of action. J. Clin. Oncol., 7:499–508, 1989.PubMedGoogle Scholar
  34. 34.
    Myers, C.E. Presentation at MSKCC.Google Scholar
  35. 35.
    Finch, P.W., Rubin, J.S., Miki T., Ron, D. and Aaronson, S.A. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science, 245:752–755, 1989.PubMedCrossRefGoogle Scholar
  36. 36.
    Chang, S-M. and Chung, L.W.K Interaction between prostatic fibroblast and epithelial cells in culture: Role of androgen. Endocrinol., 125:2719–2727, 1989.CrossRefGoogle Scholar
  37. 37.
    Chackal-Roy, M., Niemeyer, C., Moore, M. and Zetter, B.R. Stimulation human prostatic carcinoma cell growth by factors present in human bone marrow. J. Clin. Invest., 84:43–50, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Warren D. W. Heston
    • 1
  1. 1.Urologic Oncology Research LaboratoryMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations